Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended | ||||||
| · · December 31, | ||||||
| · · 2024 · · 2023 | ||||||
| | | | | | | |
| Cash Flow from Operating Activities: · · | ||||||
| Net Loss | | $(14,103,103) | | $(14,577,768) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: | | | | | ||
| Share-Based Compensation | | 2,601,903 | | 3,206,527 | ||
| Share-Based Payments to Vendors | | 833,680 | | 559,583 | ||
| (Increase)/Decrease in: | | | ||||
| Other Receivable | | | 78,032 | | | (129,159) |
| Prepaid Expenses | | 5,653 | | 159,179 | ||
| Accounts Payable and Accrued Expenses | | | 200,404 | | | 980,753 |
| Net Cash Used in Operating Activities | | | (10,383,431) | | | (9,800,885) |
| | | | | | | |
| Cash Flow from Financing Activities: | | | ||||
| Proceeds from At-the-Market Offering, net of issuance costs | | | 6,405,757 | | | 2,400,638 |
| Pre-funded Warrant Exercise | | | — | | | 73 |
| Warrant Exercise | | | 210,199 | | | 2,218,999 |
| Proceeds from 2023 Registered Direct Offering, net of issuance costs | | | — | | | 3,543,612 |
| Net Cash Provided by Financing Activities | | | 6,615,956 | | | 8,163,322 |
| Net Decrease in Cash | | (3,767,475) | | (1,637,563) | ||
| Cash at Beginning of Year | | | 7,474,188 | | | 9,111,751 |
| Cash at End of Year | | $3,706,713 | | $7,474,188 | ||
| | | | ||||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES | | | | | | |
| 2023 Registered Direct Offering costs (Note 4) | | $— | | $1,990,153 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.